EMA Withdrawn: Regranex (becaplermin) — Janssen-Cilag International NV

View source ↗

Summary

The EMA withdrew Regranex (becaplermin) from the market for wound healing and skin ulcers at Janssen-Cilag International NV on 11/10/2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin Ulcers
• Wound Healing Disorders

Drugs mentioned

• Regranex (becaplermin)

Snippet

Status: Withdrawn. Therapeutic area: Wound Healing;Skin Ulcer. MAH: Janssen-Cilag International NV. Decision date: 11/10/2010